Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Thomas E. Delea
Cost Effectiveness of Blinatumomab Versus Inotuzumab Ozogamicin in Adult Patients With Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia in the United States
PharmacoEconomics
Health Policy
Public Health
Occupational Health
Pharmacology
Environmental
Network Meta-Analysis of Progression-Free Survival and Overall Survival in First-Line Treatment of BRAF Mutation-Positive Metastatic Melanoma
Oncology and Therapy
Oncology
Related publications
Indirect Treatment Comparison of Inotuzumab Ozogamicin Versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia
Advances in Therapy
Medicine
Pharmacology
Pcn142 - Cost-Effectiveness Analysis of Inotuzumab Ozogamicin for the Treatment of Adults With Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia in Bulgaria
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Pcn71 - Budget Impact Analysis of Inotuzumab Ozogamicin for the Treatment of Adults With Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia in Bulgaria
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Initial Experience With CMC-544 (Inotuzumab Ozogamicin) in Pediatric Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia
Pediatric Blood and Cancer
Oncology
Child Health
Hematology
Perinatology
Medicine
Pediatrics
Pcn170 - Cost-Effectiveness of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: A Canadian Societal Perspective
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Pcn77 - Budget Impact Analysis of Blinatumomab for the Treatment of Pediatric Patients With Philadelphia Negative Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia in Mexico
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Efficacy and Safety Analysis by Age Cohort of Inotuzumab Ozogamicin in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia Enrolled in INO-VATE
Cancer
Cancer Research
Oncology
Pcn146 - Inotuzumab Ozogamicin in Patients With Relapsed or Refractory (R/R) Acute Lymphocytic Leukemia (All): Establishing a Value-Based Cost – Preliminary Results
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
FDA Approval: Blinatumomab for Patients With B-Cell Precursor Acute Lymphoblastic Leukemia in Morphologic Remission With Minimal Residual Disease
Clinical Cancer Research
Cancer Research
Oncology
